Scarica l'app Stockscreener
13.58
3.27%
0.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$13.15
Aprire:
$13.53
Volume 24 ore:
1.29M
Relative Volume:
1.35
Capitalizzazione di mercato:
$1.14B
Reddito:
$7.62M
Utile/perdita netta:
$-271.60M
Rapporto P/E:
-3.878
EPS:
-3.5018
Flusso di cassa netto:
$-271.54M
1 W Prestazione:
+8.64%
1M Prestazione:
+16.07%
6M Prestazione:
-20.40%
1 anno Prestazione:
+52.24%
Intervallo 1D:
$13.26
$14.03
Intervallo di 1 settimana:
$11.93
$14.03
Portata 52W:
$7.94
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Nome
Eyepoint Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
13.58 | 1.14B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Inc Borsa (EYPT) Ultime notizie
EyePoint Pharmaceuticals Inc (EYPT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
EyePoint Pharmaceuticals Inc - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
EyePoint Pharmaceuticals Inc (EYPT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
New hires at EyePoint receive 39,700 stock options package - Stock Titan
EyePoint Pharmaceuticals Inc (EYPT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
(EYPT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
EyePoint Pharmaceuticals Stock (US30233B1098): Analyst views and valuation in focus - AD HOC NEWS
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EYPT: Phase III retinal drug aims for six-month dosing, rapid vision gains, and commercial readiness - TradingView
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance - MSN
COMMODORE CAPITAL LP Increases Stake in EyePoint Inc - GuruFocus
JonesTrading Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Earnings call transcript: Eyepoint Pharmaceuticals misses Q1 2026 EPS and revenue forecasts - Investing.com
(EYPT) Risk Channels and Responsive Allocation - Stock Traders Daily
EyePoint Pharmaceuticals eyes transformative 2026 as DURAVYU Phase 3 data nears - MSN
EYPT: DURAVYU nears pivotal phase III readouts, targeting reduced treatment burden and strong safety - TradingView
Commodore Capital (EYPT) discloses 4.25M-share, 5.1% stake in EyePoint - Stock Titan
EYPT News | EYEPOINT INC (NASDAQ:EYPT) - ChartMill
EyePoint (NASDAQ: EYPT) CFO exercises RSUs, uses shares to cover tax - Stock Titan
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears - Yahoo Finance
EYPT: DURAVYU's pivotal trial results are imminent, targeting six-month dosing and market differentiation - TradingView
EYPT: DURAVYU Phase III data expected in August, targeting six-month dosing and U.S. launch in 2025 - TradingView
EyePoint (EYPT) Stifel 2026 Virtual Ophthalmology Forum Summary - Quartr
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
(EYPT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
EyePoint Inc. (EYPT) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnnual Financial Report - The Legal Advocate
How The EyePoint (EYPT) Narrative Is Evolving With DURAVYU Trials And New Analyst Targets - Yahoo Finance
EyePoint Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EyePoint Announces Participation at Upcoming Investor Conferences - The Manila Times
Should I Buy EYPT (EyePoint Pharmaceuticals, Inc.) | AI Analysis, Technical & News Insights - Kavout
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards | EYPT Stock News - Quiver Quantitative
EyePoint hands new hires 158,100 stock options at $12.35 - Stock Titan
Assessing EyePoint (EYPT) Valuation After Recent Share Price Weakness - Yahoo Finance
[SCHEDULE 13G/A] EyePoint, Inc. Amended Passive Investment Disclosure - Stock Titan
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data - Sahm
EyePoint’s DURAVYU Receives Third Consecutive Positive DSMC Review for Wet AMD - The Clinical Trial Vanguard
EyePoint Pharmaceuticals Says Phase 3 Eye Drug Trials Clear Safety Review - Moomoo
EyePoint (EYPT) Receives Positive Review for Duravyu Trials - GuruFocus
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
EyePoint Announces Third Positive DSMC Review for DURAVYU Phase 3 Wet AMD Trials, Topline Data Expected Mid-2026 - Minichart
EyePoint's late-stage eye drug trials to continue after safety panel review - TradingView
EyePoint’s wet AMD trial continues after safety review By Investing.com - Investing.com Australia
Eyepoint announces third consecutive positive DSMC recommendation for phase 3 wet AMD trials for Duravyu(TM), building confidence ahead of mid-2026 topline data - marketscreener.com
EyePoint Advances DURAVYU Phase 3 Wet AMD Program - TipRanks
EyePoint’s wet AMD trial continues after safety review - Investing.com India
EyePoint receives third positive DSMC review; Phase 3 topline data on track for mid-2026 - TradingView
Third positive DSMC review backs EyePoint (EYPT) Phase 3 DURAVYU wet AMD trials - Stock Titan
Eyepoint Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):